Source: Annual Congress 2009 - COPD case-finding and management in primary care
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
R. Wilson, M. Miravitlles, F. Kruesmann, P. Arvis (London, United Kingdom; Barcelona, Spain; Wuppertal, Germany; Lille, France). Efficacy of PO moxifloxacin in the treatment of AECOPD in patients with risk factors for poor outcomes. Eur Respir J 2009; 34: Suppl. 53, 1833

Member's Comments

No comment yet.

Related content which might interest you: Effect of daily azithromycin therapy and adherence on readmission risk in COPD Source: Eur Respir J, 53 (3) 1801377; 10.1183/13993003.01377-2018 Year: 2019 Six months azithromycin treatment in COPD patients with high risk of further exacerbations Source: International Congress 2017 – Management of COPD Year: 2017 Risk factors for discontinuation of roflumilast in COPD patients Source: International Congress 2017 – COPD management Year: 2017 Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial Source: International Congress 2018 – COPD management Year: 2018 Telithromycin is effective in the treatment of patients with acute exacerbations of chronic bronchitis and risk factors for morbidity Source: Eur Respir J 2002; 20: Suppl. 38, 545s Year: 2002 Factors influencing medication adherence amongst difficult-to-treat asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Efficacy of levofloxacin (LVF) in the treatment of acute exacerbations of chronic bronchitis (AECB) in patients with risk factors Source: Annual Congress 2003 - Acute exacerbations of asthma and COPD Year: 2003 Factors affecting the efficacy of treatment of MDR/XDR TB patients receiving bedaquiline Source: International Congress 2019 – Tuberculosis: a public health approach Year: 2019 Influence of statin therapy on clinical symptoms, severity and prognosis in patients with community acquired pneumonia Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia Year: 2008 Comparison of hospitalization risk for Medicaid patients with COPD by medication regimen Source: Eur Respir J 2003; 22: Suppl. 45, 375s Year: 2003 Long-term treatment with clarithromycin of stage II COPD patients with frequent exacerbations Source: Annual Congress 2008 - Management of COPD Year: 2008 Efficacy of different dosing regimens of azithromycin in a real-world severe asthma cohort Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Risk factors for antibiotic re-administration in patients with pneumonia during hospitalization. Source: International Congress 2018 – Improving the outcomes of community-acquired pneumonia Year: 2018 Compliance to asthma treatment and its risk factors Source: Eur Respir J 2005; 26: Suppl. 49, 508s Year: 2005 Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Comparison of treatment outcomes in community-acquired pneumonia patients treated with beta lactam-macrolide combination versus fluoroquinolone monotherapy Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012 Efficacy of α-tocoferol in the treatment of patients with pneumonia Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 Factors associated with poor prognostic outcome in acute exacerbation of COPD Source: Annual Congress 2009 - Treatment of airways disease Year: 2009 Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia Source: Eur Respir J 2003; 21: 135-143 Year: 2003 Impact of roflumilast treatment on the rate and duration of exacerbations and overall steroid load in patients with COPD Source: Annual Congress 2011 - COPD management Year: 2011